The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial. - Hawkins PCT; Schwarz AJ; Stone JM; Pepper F; Gilleen J; Gijsen S; Mazibuko N; Arkilo D; Yin W; Wu J; Khudyakov P; Behrje R; et al. (Psychopharmacology, 2026)